Nuvalent to Participate in the Cantor Global Healthcare Conference 2025
Rhea-AI Summary
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming Cantor Global Healthcare Conference 2025. The company's leadership, including CEO James Porter, Ph.D., and CFO Alexandra Balcom, will engage in a fireside chat on September 4, 2025, at 9:45 a.m. ET in New York City.
Investors can access a live webcast of the presentation through Nuvalent's website, where it will remain available for 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – NUVL
In the Aug 28 session, NUVL declined 0.14%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-cantor-global-healthcare-conference-2025-302540438.html
SOURCE Nuvalent, Inc.